Evolus, Inc. (NASDAQ:EOLS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Evolus, Inc. (NASDAQ:EOLS) have earned an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $17.50.

A number of analysts have commented on the company. Wall Street Zen raised Evolus from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. HC Wainwright dropped their price objective on Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Mizuho set a $15.00 price objective on Evolus in a report on Wednesday, February 4th. Needham & Company LLC restated a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. Finally, BTIG Research dropped their price target on shares of Evolus from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday, January 22nd.

Evolus Price Performance

NASDAQ:EOLS opened at $4.30 on Thursday. The firm’s 50-day moving average price is $5.86 and its 200-day moving average price is $6.57. The company has a market capitalization of $278.73 million, a PE ratio of -4.67 and a beta of 1.11. Evolus has a 1-year low of $4.09 and a 1-year high of $17.12.

Insider Transactions at Evolus

In related news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the sale, the insider owned 354,388 shares in the company, valued at approximately $2,533,874.20. This trade represents a 2.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Evolus

Several hedge funds and other institutional investors have recently modified their holdings of EOLS. Manchester Capital Management LLC bought a new stake in shares of Evolus in the second quarter worth $26,000. State of Alaska Department of Revenue purchased a new position in Evolus in the third quarter worth about $26,000. Larson Financial Group LLC grew its stake in shares of Evolus by 136.6% during the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after purchasing an additional 2,837 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Evolus during the 4th quarter valued at about $34,000. Finally, Wexford Capital LP purchased a new stake in shares of Evolus during the 3rd quarter valued at about $37,000. 90.69% of the stock is owned by institutional investors.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.